Cancer-Killing virus trial launches for patients out of options

NCT ID NCT06910657

Recruiting now Disease control Sponsor: ViroMissile, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 5 times

Summary

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments. Participants receive a single intravenous dose, and researchers will monitor safety, side effects, and any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IDOV-Immune (a genetically engineered virus that targets and kills cancer cells)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 78 participants, so it is not yet known if the treatment is safe or effective. There is a risk of side effects from the virus, and the therapy may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL GLAND TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal gland cancer adrenal gland neoplasm breast cancer breast neoplasm cervical cancer cervical carcinoma colorectal cancer colorectal neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm head and neck cancer Head and Neck Neoplasms hepatocellular carcinoma lung cancer lung neoplasm malignant pancreatic neoplasm melanoma neoplasm Neoplasm Metastasis ovarian cancer pancreatic neoplasm prostate cancer renal cell carcinoma sarcoma urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms vaccinia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL GLAND TUMORS BLADDER CANCER BREAST CANCER CERVICAL CANCERS COLORECTAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER HEAD AND NECK CANCERS HEPATOCELLULAR CARCINOMA LUNG CANCER MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CELL CARCINOMA SARCOMA

Contacts and locations

Show contact details

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
South Texas Accelerated Research Therapeutics
RECRUITING

San Antonio, Texas, 78229, United States

Contact Email: •••••@•••••
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Westmead Hospital
RECRUITING

Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.